OakChart

TELA Bio Inc

TELAHealthcare·Medical Devices·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.9418+0.1418 (17.72%)
2026-11-12 05:30 CET
Market cap
42.52 USD m
Revenue, TTM
78.18 USD m
Net income, TTM
-41.88 USD m
Free cash flow, TTM
-34.39 USD m
EPS diluted, TTM
-0.75
P/E
-
Compare

Price

TELA against its 20, 50 and 200-day averages
2050200beatmiss
0.751.001.251.501.0M2.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TELAclose 0.9420-day 0.9250-day 1.03200-day 0.850.9452w high

37.2% under the 52-week high of 1.50 on 23 Sep 2026. 52-week low 0.50 on 2 Apr 2026. Last 15 sessions, 65.2% high to low

Volume 3.55× normal · the line is the 50-bar volume average

Profile

TELA
52-week range, 44% of the way up
0.501.50

TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.

Employees218
IPONov 08, 2019
Beta1.46
ATR, 14d0.13
Rel volume3.55
Short float1.73%
Insider own25.99%
Inst own43.43%

Snapshot

6 groups

Valuation

Index-
Market Cap42.51M
Enterprise Value76.68M
Income-41.88M
Sales78.18M
Book/sh-0.54
Cash/sh0.50
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees218
IPONov 08, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S0.54
P/B-
P/C1.88
P/FCF-
EV/EBITDA-
EV/Sales0.98
Quick Ratio0.45
Current Ratio0.61
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.75
EPS next Y-0.44
EPS next Q-0.12
EPS this Y19.94%
EPS next Y33.15%
EPS next 5Y25.43%
EPS past 3/5Y32.78% 17.97%
Sales past 3/5Y24.68% 34.54%
EPS Y/Y TTM15.79%
Sales Y/Y TTM1.46%
EPS Q/Q14.89%
Sales Q/Q-8.36%
EarningsNov 10 AMC
EPS/Sales Surpr.19.15% -5.21%

Ownership

Insider Own25.99%
Insider Trans1.54%
Inst Own43.43%
Inst Trans-3.69%
ROA-75.40%
ROE-616.62%
ROIC-
Gross Margin67.19%
Oper. Margin-40.63%
Profit Margin-53.57%
SMA202.41%
SMA50-8.50%
SMA20010.66%
Trades-

Technical

Shs Outstand45.14M
Shs Float33.41M
Short Float1.73%
Short Ratio2.66
Short Interest0.58M
52W High1.50 -37.21%
52W Low0.50 87.95%
Volatility19.87% 14.08%
ATR (14)0.13
RSI (14)50.53
Beta1.46
Rel Volume3.55
Avg Volume217.91K
Volume774,187

Performance

Perf Week12.41%
Perf Month-11.57%
Perf Quarter38.91%
Perf Half Y-1.90%
Perf YTD-20.19%
Perf Year-20.86%
Perf 3Y-79.61%
Perf 5Y-92.42%
Perf 10Y-
Recom1.40
Target Price1.80
Prev Close0.80
Price0.94
Change %17.72%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Sep 25, 2026InitiatedCCraig HallumBuy$2+112.4%
Mar 21, 2025DowngradePPiper SandlerOverweight → Neutral$5 → $2+112.4%
May 31, 2022InitiatedLLake StreetBuy$17+1,705.1%
Dec 03, 2019InitiatedPPiper JaffrayOverweight
Dec 03, 2019InitiatedJJMP SecuritiesMkt Outperform
Dec 03, 2019InitiatedJJefferiesBuy
Dec 03, 2019InitiatedCCanaccord GenuityBuy

Peers

Mkt cap
TickerCompanyMkt cap
ELUTElutia Inc40.75M
IARTIntegra Lifesciences Holdings Corp1.15B
XTNTXtant Medical Holdings Inc38.99M
AXGNAxogen Inc3.50B
RCELAVITA Medical Inc429.73M
BVSBioventus Inc926.03M
ORGOOrganogenesis Holdings Inc136.29M
MDXGMimedx Group Inc484.47M
SMTISanara MedTech Inc290.43M
ANIKAnika Therapeutics Inc186.86M

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Capper Joseph HDirectorSep 16 '26Buy1.1750,00058,265154,827Sep 18 04:30 PM
Capper Joseph HDirectorSep 17 '26Buy1.2225,00030,530179,827Sep 18 04:30 PM
Capper Joseph HDirectorSep 15 '26Buy1.0650,00052,940104,827Sep 16 06:46 PM
Capper Joseph HDirectorSep 14 '26Buy1.0225,00025,50254,827Sep 16 06:46 PM
Getz Heather CChief Executive OfficerAug 17 '26Buy0.6612,5008,311532,500Aug 19 04:10 PM
Getz Heather CChief Executive OfficerAug 14 '26Buy0.7015,00010,467520,000Aug 17 04:32 PM
EW HEALTHCARE PARTNERS FUND 2,10% OwnerNov 17 '25Buy1.113,604,0004,000,4407,714,709Nov 17 04:26 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • TELA Bio Beats On Cost Cuts, But Shrinking Revenue And A Thinning Cash Cushion Define The Quarter (Earnings Whispers) -7.47% +17.72%
  • TELA Bio Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.13% +5.44%
  • TELA Bio Heads Into Q3 With New CEO, No Guidance And A Shrinking Cash Cushion (Earnings Whispers)
  • TELA Bio to Announce Third Quarter 2026 Financial Results (GlobeNewswire)
  • TELA Bio Announces 510(k) Clearance for Liora Monofilament Scaffold for Soft Tissue Reinforcement (GlobeNewswire)
  • TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative (GlobeNewswire) +5.43%
  • TELA Bio Inc (TELA) (Q2 2026) Earnings Call Highlights: Navigating PRS Headwinds and Strategic ... (GuruFocus.com) -15.05%
  • TELA Bio Reports Second Quarter 2026 Financial Results (GlobeNewswire) +6.91%
  • Earnings To Watch: TELA Bio Inc (TELA) Q2 2026 -- GF Value Sees 97% Upside (GuruFocus.com)
  • TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.01%
  • TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director (GlobeNewswire) +22.51%
  • TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference (GlobeNewswire)
  • TELA Bio to Announce Second Quarter 2026 Financial Results (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.130-0.161-0.16118.9620.005
2026Q22026-08-10-0.200-0.174-0.19619.2920.015
2026Q12026-05-12-0.210-0.184-0.21419.0618.605
2025Q42026-03-24-0.170-0.178-0.17520.8721.035
2025Q32025-11-13-0.190-0.193-0.18920.6921.785
2025Q22025-08-11-0.220-0.176-0.21920.2020.675
2025Q12025-05-08-0.250-0.196-0.24918.5217.365
2024Q42025-03-20-0.230-0.212-0.23017.6523.195
2024Q32024-11-07-0.420-0.405-0.42018.9618.855
2024Q22024-08-12-0.510-0.457-0.51116.0918.455
2024Q12024-05-09-0.230-0.489-0.23016.6016.325
2023Q42024-03-21-0.530-0.446-0.52617.0016.465
2023Q32023-11-09-0.450-0.481-0.44815.0516.215
2023Q22023-08-09-0.460-0.522-0.46414.4914.395
2023Q12023-05-11-0.630-0.547-0.62711.9112.015
2022Q42023-03-21-0.520-0.533-0.52111.6213.185

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-17.100-2.343-2.64815.4514.78
2020FY-2.230-2.137-2.22618.2118.33
2021FY-2.300-2.176-2.29929.4629.04
2022FY-2.720-2.729-2.72341.4243.00
2023FY-2.040-1.935-2.04158.4557.95
2024FY-1.330-1.374-1.32769.3074.71
2025FY-0.830-0.818-0.83080.2880.44
2026FY--0.665--78.10
2027FY--0.444--84.01
2028FY--0.344--92.34

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-1150220.1519.0721.19
2026Q4S2026-11-1050021.1620.3022.30
2026Q4S2026-10-2550021.1620.3022.30
2026Q4S2026-10-1550421.1620.3022.30
2026Q4S2026-09-2460521.2020.3022.30
2026Q4S2026-08-2150521.2420.3022.30
2026Q4S2026-08-1450521.2420.3022.30
2026Q4S2026-08-1150521.2420.3022.30
2026Q4S2026-08-1050024.8624.3025.20
2026Q4S2026-07-2750024.8624.3025.20
2026Q4S2026-06-0652024.8624.3025.20
2026Q4S2026-05-1353024.8624.3025.20
2026Q4S2026-04-3050224.6324.4025.00
2026Q4S2026-03-2550224.6324.4025.00

Estimate history

EPS, annual-2.422-2.661-2.648-2.226-2.299-2.723-2.041-1.327-0.827-0.7467
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.42-0.23-0.249-0.219-0.189-0.175-0.214-0.196-0.161
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual4.2458.27415.44618.21329.46341.41858.45369.380.27578.18
Period201720182019202020212022202320242025TTM
Sales, quarterly18.95717.64918.5220.19720.68920.86919.05919.29118.959
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual11.24211.24211.40614.43714.5319.16524.49539.39644.53845.143
Period201720182019202020212022202320242025MRQ
Shares, quarterly24.71739.39639.55539.58440.34244.53844.76644.83445.143
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue78.1880.2869.3058.4541.4229.4618.2115.458.27
Cost of Goods Sold Incl. D&A25.6525.9322.8118.3414.3710.656.986.175.33
Gross Profit52.5354.3446.4940.1127.0418.8111.239.272.94
Selling, General and Administrative Excl. Other84.2988.1088.1884.1966.0548.2636.5128.4322.88
Research and Development8.809.228.819.628.946.744.254.154.34
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-31.76-33.76-41.70-44.08-39.01-29.45-25.27-19.16-19.94
Interest Expense7.875.255.295.224.053.603.563.611.80
Unusual Expense2.870.890.000.001.230.000.000.01-0.58
Net Income Before Taxes-41.51-38.60-37.98-46.66-44.30-33.28-28.79-22.43-21.09
Income Taxes0.370.23-0.140.000.000.000.000.000.00
Consolidated Net Income-41.88-38.83-37.84-46.66-44.30-33.28-28.79-22.43-21.09
Net Income From Continuing Operations-41.88-38.83-37.84-46.66-44.30-33.28-28.79-22.43-21.09
Net Income-41.88-38.83-37.84-46.66-44.30-33.28-28.79-30.21-29.91
EPS (Recurring)-0.69-0.81-1.33-2.04-2.67-2.30-2.23-2.65-2.70
EPS (Basic, Before Extraordinaries)-0.75-0.83-1.33-2.04-2.72-2.30-2.23-2.65-2.66
EPS (Diluted)-0.75-0.83-1.33-2.04-2.72-2.30-2.23-2.65-2.66
EBITDA-30.74-32.74-40.68-43.27-37.82-28.92-24.75-18.58-18.69
Non-Operating Income (Expense)0.991.299.002.63-0.01-0.230.040.350.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.263.003.455.033.993.662.060.460.17
Price To Sales Ratio0.850.691.242.594.526.2910.689.56-
Gross Margin67.1967.6967.0868.6265.3063.8561.6860.0335.56
Operating Margin-40.63-42.05-60.17-75.40-94.18-99.96-138.77-124.06-241.02
Net Margin-53.57-48.37-54.60-79.83-106.95-112.94-158.10-195.57-361.55
Shares Outstanding45.1444.5439.4024.4919.1714.5314.4411.4111.24
Market Capitalization42.5242.52118.95162.12220.33185.65217.06147.71142.80

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue18.9619.2919.0620.8720.6920.2018.5217.65
Cost of Goods Sold Incl. D&A6.655.356.547.116.726.096.016.43
Gross Profit12.3113.9412.5213.7613.9714.1112.5111.22
Selling, General and Administrative Excl. Other17.6123.2323.0520.4021.5223.1922.9819.57
Research and Development1.602.722.342.132.352.202.542.03
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.31-9.28-10.53-6.65-7.55-9.08-10.47-8.35
Interest Expense2.102.082.051.641.201.191.221.28
Unusual Expense1.980.000.000.890.000.000.000.00
Net Income Before Taxes-9.20-11.20-12.21-8.90-8.60-9.89-11.21-9.35
Income Taxes0.100.060.060.140.000.030.05-0.14
Consolidated Net Income-9.30-11.26-12.27-9.04-8.60-9.92-11.26-9.21
Net Income From Continuing Operations-9.30-11.26-12.27-9.04-8.60-9.92-11.26-9.21
Net Income-9.30-11.26-12.27-9.04-8.60-9.92-11.26-9.21
EPS (Recurring)-0.14-0.20-0.21-0.16-0.19-0.22-0.25-0.23
EPS (Basic, Before Extraordinaries)-0.16-0.20-0.21-0.17-0.19-0.22-0.25-0.23
EPS (Diluted)-0.16-0.20-0.21-0.17-0.19-0.22-0.25-0.23
EBITDA-5.04-9.02-10.26-6.42-7.31-8.81-10.21-8.09
Non-Operating Income (Expense)0.190.160.370.280.150.380.480.28
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.490.480.640.640.950.780.820.17
Price To Sales Ratio0.850.540.440.760.881.170.781.75
Gross Margin64.9272.2865.6965.9167.5269.8467.5663.58
Operating Margin-27.99-48.12-55.23-31.86-36.51-44.96-56.54-47.33
Net Margin-49.06-58.38-64.39-43.32-41.58-49.13-60.82-52.17
Shares Outstanding45.1444.8344.7744.5440.3439.5839.5539.40
Market Capitalization42.5233.5727.7452.5559.0376.7448.25118.95

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments50.8452.6746.7342.0243.9374.3954.5917.2811.35
Short Term Receivables11.9510.109.746.624.232.682.841.300.76
Inventories11.0212.7813.1611.797.663.914.604.351.81
Other Current Assets1.772.522.102.023.232.242.310.330.43
Total Current Assets75.5878.0771.7362.4559.0583.2264.3323.2514.35
Net Property, Plant & Equipment3.734.083.942.911.190.630.680.761.16
Total Investments and Advances0.250.270.270.000.000.000.000.000.02
Long-Term Note Receivable-2.28-------
Intangible Assets1.361.742.122.502.302.612.913.210.00
Deferred Tax Assets0.610.90-------
Other Assets0.500.000.000.000.000.000.000.000.00
Total Assets82.0387.3378.0567.8662.5486.4667.9227.2315.53
Short Term Debt Incl. Current Port. of LT Debt0.520.550.560.340.000.000.000.000.91
Accounts Payable2.312.151.671.532.410.653.173.421.51
Other Current Liabilities15.1412.9114.7310.538.165.953.546.143.74
Total Current Liabilities17.9815.6016.9712.4010.576.616.719.566.15
Long Term Debt57.1342.5142.2041.1231.4930.8330.2431.375.31
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.610.76-------
Other Liabilities0.000.000.000.030.380.000.000.010.90
Total Liabilities75.7158.8759.1753.5542.4537.4336.9640.9412.35
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00124.15111.35
Common Equity6.3128.4618.8814.3020.1049.0330.96-137.86-108.17
Total Shareholders Equity6.3128.4618.8814.3020.1049.0330.96-13.713.18
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity6.3128.4618.8814.3020.1049.0330.96-13.713.18
Total Liabilities & Stockholders Equity82.0387.3378.0567.8662.5486.4667.9227.2315.53
Book Value Per Share0.140.720.770.751.383.402.71-12.26-9.62
Tangible Book Value Per Share0.110.680.680.621.223.222.46-12.55-9.62
Full-Time Employees21820922717312310889--
Price to Book Ratio-1.73-11.905.319.469.254.434.77-0.89-
Return on Assets-45.86-45.76-63.97-67.94-44.67-37.30-47.14-98.66-
Return on Equity-223.35-159.87-281.23-257.51-96.28-72.00-259.97--
Return on Invested Capital-61.21-53.32-76.40-79.93-64.50-36.06-36.64-119.41-251.43
Quick Ratio3.594.193.454.084.8612.018.901.982.04
Current Ratio4.205.014.235.035.5812.609.582.432.33

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-41.88-38.83-37.84-46.66-44.30-33.28-28.79-22.43-21.09
Depreciation1.021.011.010.811.190.540.530.581.25
Other Funds (Non Cash)7.738.110.256.987.705.773.972.584.38
Funds from Operations-33.06-29.72-36.73-38.87-35.41-26.98-24.30-19.27-15.47
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.051.50-4.87-1.99-5.34-3.46-0.16-6.26-4.48
Cash from Operating Activities-34.11-28.22-41.59-40.86-40.75-30.43-24.46-25.52-19.95
Capital Expenditures-0.28-0.45-0.99-0.61-1.87-0.63-0.17-2.70-1.56
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses1.911.295.440.010.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.009.29-9.280.00
Purchase of Investments0.000.000.000.000.000.000.00-9.280.00
Sale Or Maturity of Investments0.000.000.000.000.000.009.290.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities1.640.854.45-0.60-1.87-0.639.12-11.98-1.56
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock11.8711.9343.4346.5634.470.5844.4165.532.41
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock11.8711.9343.4346.5634.470.5844.4165.532.41
Proceedsfrom Stock Options11.9311.9343.2046.4334.450.0444.2365.522.41
Issuance or Reduction of Debt, Net14.0314.030.000.006.540.000.000.0025.00
Change in Long Term Debt14.0314.030.000.006.540.000.000.0025.00
Issuance of Long Term Debt56.4556.450.000.0036.540.000.000.0043.73
Reduction of Long Term Debt-42.42-42.420.000.00-30.000.000.000.00-18.73
Net Financing Active Other Cash Flow-0.42-0.20-0.37-0.29-0.160.000.000.000.00
Other Financing Activities Uses-0.42-0.20-0.37-0.29-0.160.000.000.000.00
Cash from Financing Activities25.4825.7543.0646.2740.850.5844.4165.5327.41
Exchange Rate Effect-0.10-0.220.030.16-0.140.010.02-0.00-
Net Change in Cash-7.10-1.845.944.97-1.91-30.4629.0928.025.91
Free Cash Flow-34.39-28.67-42.58-41.47-41.62-31.06-24.62-25.72-20.01
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00--
Deferred Taxes & Investment Tax Credit-0.00-0.140.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments22.6630.4239.5450.8429.7134.98
Short Term Receivables9.2710.6411.0211.9513.1712.54
Inventories11.6111.0612.2111.0211.5611.37
Other Current Assets1.052.371.531.771.601.86
Total Current Assets44.6054.4964.3075.5856.0560.74
Net Property, Plant & Equipment3.193.433.603.733.773.78
Total Investments and Advances0.200.200.250.250.250.27
Intangible Assets1.071.171.261.361.451.55
Deferred Tax Assets---0.610.060.06
Other Assets0.420.450.480.500.000.00
Total Assets49.4959.7469.8982.0361.5967.54
Short Term Debt Incl. Current Port. of LT Debt56.830.530.530.520.523.85
Accounts Payable2.392.883.892.312.371.74
Other Current Liabilities13.6314.8013.4115.1414.0813.47
Total Current Liabilities72.8618.2217.8317.9816.9819.06
Long Term Debt0.0056.0855.8757.1341.4938.05
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.61--
Other Liabilities1.211.301.390.001.561.24
Total Liabilities74.0775.6075.0975.7160.0358.35
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-24.58-15.87-5.206.311.569.18
Total Shareholders Equity-24.58-15.87-5.206.311.569.18
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-24.58-15.87-5.206.311.569.18
Total Liabilities & Stockholders Equity49.4959.7469.8982.0361.5967.54
Book Value Per Share-0.54-0.35-0.120.140.040.23
Tangible Book Value Per Share-0.57-0.38-0.140.110.000.19
Full-Time Employees---218--
Price to Book Ratio-1.73-6.464.3730.576.424.23
Return on Assets-75.40-64.71-54.15-45.86-68.06-63.83
Return on Equity---616.62-223.35--676.41
Return on Invested Capital--28.00-24.22-14.25-19.98-21.01
Quick Ratio0.452.382.923.592.622.59
Current Ratio0.612.993.614.203.303.19

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-9.30-11.26-12.27-9.04-8.60-9.92
Depreciation0.270.270.260.230.250.27
Other Funds (Non Cash)1.731.131.992.892.071.35
Funds from Operations-7.28-9.81-9.96-6.01-6.28-8.27
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.410.43-1.211.150.560.37
Cash from Operating Activities-8.69-9.38-11.17-4.87-5.72-7.91
Capital Expenditures-0.01-0.06-0.12-0.09-0.21-0.11
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses1.020.300.310.280.520.32
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities1.020.240.190.190.310.20
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.020.000.0311.820.040.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.020.000.0311.820.040.00
Proceedsfrom Stock Options0.000.000.0011.930.000.00
Issuance or Reduction of Debt, Net0.000.000.0014.030.000.00
Change in Long Term Debt0.000.000.0014.030.000.00
Issuance of Long Term Debt0.000.000.0056.450.000.00
Reduction of Long Term Debt0.000.000.00-42.420.000.00
Net Financing Active Other Cash Flow-0.07-0.01-0.33-0.00-0.02-0.00
Other Financing Activities Uses-0.07-0.01-0.33-0.00-0.02-0.00
Cash from Financing Activities-0.05-0.01-0.3025.840.02-0.00
Exchange Rate Effect-0.03-0.01-0.03-0.040.10-0.15
Net Change in Cash-7.76-9.17-11.3021.13-5.28-7.86
Free Cash Flow-8.70-9.44-11.29-4.96-5.93-8.02

Revenue breakdown

Surgical & Medical Instruments & Apparatus2024: 69.30M 2025: 80.28M
United States2024: 69.30M 2025: 80.28M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.73%0.6M33.4M230.27K
2026-10-151.91%0.6M33.4M216.47K
2026-09-301.40%0.5M33.4M202.37K
2026-09-151.65%0.6M33.4M178.02K
2026-08-311.18%0.4M32.5M155.67K
2026-08-141.04%0.3M32.4M114.76K
2026-07-311.04%0.3M32.9M128.16K
2026-07-151.10%0.4M32.9M156.85K
2026-06-301.42%0.5M32.9M175.00K
2026-06-150.92%0.3M32.9M193.21K
2026-05-291.83%0.7M40.8M183.72K
2026-05-152.39%0.8M33.0M182.16K
2026-04-302.35%0.8M32.6M225.05K
2026-04-152.32%0.8M32.6M205.20K
2026-03-312.08%0.7M33.2M187.62K
2026-03-131.75%0.6M33.1M161.37K
2026-02-271.90%0.6M33.1M187.03K
2026-02-131.95%0.6M33.1M252.06K
2026-01-301.54%0.5M33.1M176.41K
2026-01-151.44%0.5M33.1M181.20K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.100.006.4940.000.000.295-0.0150.000
call5.000.003.800.008.0430.000.000.239-0.0210.000
call7.500.003.800.009.1140.000.000.225-0.0230.000
put2.500.004.900.000.0000.000.00-0.700-0.0160.000
put5.002.306.500.000.0000.000.00-0.761-0.0200.000
put7.504.509.000.000.0000.000.00-0.775-0.0220.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-088-KCurrent report2026-10-08SEC
2026-10-068-KCurrent report2026-10-05SEC
2026-10-058-KCurrent report2026-10-05SEC
2026-09-298-KCurrent report2026-09-28SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-188-KCurrent report2026-09-15SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-14DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-08SEC
2026-09-04PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-08SEC
2026-08-318-KCurrent report2026-08-28SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-138-K/A2026-08-03SEC
2026-08-11S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-11SCHEDULE 13GSEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-053Initial statement of beneficial ownership of securities2026-08-03SEC
2026-08-04S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-048-KCurrent report2026-08-03SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09167.24K400
2026-0818.78K200
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-114.00M100

Institutional holders

Manager% owned
Nantahala Capital Management, LLC26.33%
Essex Woodlands Management, Inc.17.09%
Stonepine Capital Management, LLC5.95%
SILVERARC CAPITAL MANAGEMENT, LLC4.77%
PERKINS CAPITAL MANAGEMENT INC4.61%
VANGUARD CAPITAL MANAGEMENT LLC3.50%
DAFNA Capital Management LLC3.22%
Sio Capital Management, LLC1.42%
WealthTrust Axiom LLC1.22%
GEODE CAPITAL MANAGEMENT, LLC0.91%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.57%
VANGUARD EXTENDED MARKET INDEX FUND0.87%
Fidelity Extended Market Index Fund0.42%
Fidelity Total Market Index Fund0.15%
Fidelity Series Total Market Index Fund0.12%
Jacob Discovery Fund0.09%
Jacob Small Cap Growth Fund0.09%
VANGUARD BALANCED INDEX FUND0.06%
Fidelity Nasdaq Composite Index Fund0.03%
Knights of Columbus U.S. ALL CAP INDEX FUND0.00%

OakChart. TELA. Cached 15 minutes.